EIF3K

Eukaryotic translation initiation factor 3 subunit K · Q9UBQ5 · EIF3K on Sugi Atlas →

0 patent compounds predicted against EIF3K, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF3K by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a EIF3K binder may also engage these)

ProteinNameSimilarity
Q3T0V3 1.000 Q3T0V3 →
Q9DBZ5 1.000 Q9DBZ5 →
Q28C65 0.986 Q28C65 →
Q6GNI4 0.971 Q6GNI4 →
Q5ZLA5 0.969 Q5ZLA5 →
EIF3E Eukaryotic translation initiation factor 3 subunit E 0.966 landscape →
PSMD13 26S proteasome non-ATPase regulatory subunit 13 0.965 landscape →
Q3T102 0.965 Q3T102 →
Q4R6G8 0.965 Q4R6G8 →
P60229 0.965 P60229 →
Q5R8K9 0.965 Q5R8K9 →
Q641X8 0.964 Q641X8 →
Q8VBV7 0.963 Q8VBV7 →
B5DGH9 0.962 B5DGH9 →
Q05AY2 0.962 Q05AY2 →
O88544 0.962 O88544 →
Q5E964 0.962 Q5E964 →
Q5RF54 0.962 Q5RF54 →
Q6P7L9 0.961 Q6P7L9 →
Q9WVJ2 0.961 Q9WVJ2 →
Q5R5F8 0.961 Q5R5F8 →
Q6DRI1 0.961 Q6DRI1 →
GPS1 COP9 signalosome complex subunit 1 0.961 landscape →
Q3SZA0 0.960 Q3SZA0 →
Q9NVE7 0.960 Q9NVE7 →
Q4R4U1 0.960 Q4R4U1 →
Q6P4Z9 0.959 Q6P4Z9 →
Q3B8M3 0.959 Q3B8M3 →
P84169 0.959 P84169 →
Q68FS2 0.959 Q68FS2 →